PARP抑制剂治疗卵巢癌的应用现况及进展
Current Status and Progress of PARP Inhibitors in the Treatment of Ovarian Cancer
DOI: 10.12677/ACM.2023.1361346, PDF,   
作者: 郑建勋, 马彩玲*：新疆医科大学第一附属医院妇科，新疆 乌鲁木齐
关键词: PARP抑制剂；卵巢恶性肿瘤；无进展生存期；PARP Inhibitor； Ovarian Malignancy； Progression-Free Survival
摘要: 随着聚腺苷二磷酸核糖聚合酶抑制剂(PARP抑制剂)的出现，很大程度上改善卵巢恶性肿瘤患者的无进展生存时间总的存活率，本文主要介绍了PARP抑制剂的作用机制，市场上常见的几种PARP抑制剂，及其适应症以及未来PARP抑制剂的应用前景及其不足。
Abstract: With the emergence of poly ADP-ribose polymerase inhibitors (PARP inhibitors), the overall pro-gression-free survival rate of patients with ovarian malignant tumors has been improved to a large extent. This mainly introduces the mechanism of action of PARP inhibitors, several common PARP inhibitors on the market, their indications, and the application prospects and shortcomings of PARP inhibitors in the future.
文章引用：郑建勋, 马彩玲. PARP抑制剂治疗卵巢癌的应用现况及进展[J]. 临床医学进展, 2023, 13(6): 9619-9623. https://doi.org/10.12677/ACM.2023.1361346

参考文献

[1] 余敏华, 金明珠, 狄文. Parp抑制剂卵巢癌治疗研究进展[J]. 现代妇产科进展, 2021, 30(6): 470-474.
[2] 周琦, 吴小华, 刘继红, 等. 中国卵巢上皮性癌维持治疗专家共识(2019) [J]. 中国实用妇科与产科杂志, 2019, 35(6): 655-659.
[3] 李晶, 吴妙芳, 林仲秋. 《FIGO 2021妇癌报告》——卵巢癌、输卵管癌、腹膜癌诊治指南解读[J]. 中国实用妇科与产科杂志, 2022, 38(3): 301-309.
[4] 刘畅浩, 林少丹, 林仲秋. 《PARP抑制剂在卵巢癌中的应用: ASCO指南》解读[J]. 中国实用妇科与产科杂志, 2020, 36(9): 835-839.
[5] 中华医学会妇科肿瘤学分会, 孔北华, 刘继红, 等. 卵巢癌PARP抑制剂临床应用指南(2022版) [J]. 现代妇产科进展, 2022, 31(8): 561-572.
[6] 储慧慧, 刘倩. 卵巢癌临床治疗的研究进展[J]. 国际妇产科学杂志, 2021, 48(4): 443-447, 466.
[7] Ledermann, J.A., Harter, P., Gourley, C., et al. (2016) Overall Survival in Patients with Platinum-Sensitive Recurrent Serous Ovarian Cancer Receiving Olaparib Maintenance Monotherapy: An Updated Analysis from a Randomised, Placebo-Controlled, Double-Blind, Phase 2 Trial. The Lancet Oncology, 17, 1579-1589. [Google Scholar] [CrossRef] 
[8] Mirza, M.R., Monk, B.J., Herrstedt, J., et al. (2016) Ni-raparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. The New England Journal of Medicine, 375, 2154-2164. [Google Scholar] [CrossRef] 
[9] Wu, X.H., Zhu, J.Q., Yin, R.T., et al. (2021) Ni-raparib Maintenance Therapy in Patients with Platinum-Sensitive Recurrent Ovarian Cancer Using an Individualized Starting Dose (NORA): A Randomized, Double-Blind, Placebo-Controlled Phase III Trial. Annals of Oncology, 32, 512-521. [Google Scholar] [CrossRef] [PubMed]
[10] 卢淮武, 吴斌, 许妙纯, 等. 《2022 NCCN卵巢癌包括输卵管癌及原发性腹膜癌临床实践指南(第1版)》解读[J]. 中国实用妇科与产科杂志, 2022, 38(3): 310-318.
[11] Zheng, H., Gao, Y., Guo, H., et al. (2021) Real-World Experience of Olaparib Treatment in Patients with Ovarian Cancer: A Chinese Multicenter Study. Molecular Cancer Therapeutics, 20, 1735-1742. [Google Scholar] [CrossRef] 
[12] Ding, L., Kim, H.J., Wang, Q., et al. (2018) PARP Inhibi-tion Elicits Sting-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer. Cell Reports, 25, 2972-2980.E5. [Google Scholar] [CrossRef] [PubMed]
[13] Shen, J., Zhao, W., Ju, Z., et al. (2019) PARPi Triggers the Sting-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independ-ent of BRCAness. Cancer Research, 79, 311-319. [Google Scholar] [CrossRef] 

为你推荐